Determinants of differential doxorubicin sensitivity between SCLC and NSCLC  by Singhal, Sharad S. et al.
FEBS Letters 580 (2006) 2258–2264Determinants of diﬀerential doxorubicin sensitivity between
SCLC and NSCLC
Sharad S. Singhala, Dilki Wickramarachchia, Jyotsana Singhala, Sushma Yadava,
Yogesh C. Awasthib, Sanjay Awasthia,*
a Department of Chemistry and Biochemistry, University of Texas at Arlington, 401 W, 3rd Street, CPB RM # 312, Arlington,
TX 76019-0065, United States
b Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch at Galveston, Galveston, TX 77555, United States
Received 2 December 2005; revised 6 March 2006; accepted 8 March 2006
Available online 24 March 2006
Edited by Veli-Pekka LehtoAbstract Doxorubicin (DOX) transport activity of Ral-inter-
acting protein (RLIP76) in non-small cell lung cancer (NSCLC)
is approximately twice that of in small cell lung cancer (SCLC).
Since protein-kinase-C (PKC)a mediated phosphorylation of
RLIP76 causes doubling of the speciﬁc activity of RLIP76,
and NSCLC cells are known to have greater PKCa activity,
we examined the contribution of PKC mediated phosphorylation
of RLIP76 towards intrinsic DOX-resistance in human NSCLC.
Expression of a deletion mutant RLIP76delPKCa-sites followed by
depletion of the wild-type RLIP76 using a siRNA targeted at one
of the deleted regions resulted in generation of cells expressing
only the mutant protein, which could not be phosphorylated by
PKCa. DOX-transport activity of the mutant RLIP76 puriﬁed
from NSCLC and SCLC was similar and comparable to that
of RLIP76 puriﬁed from the wild-type SCLC. However, this
activity was signiﬁcantly lower than that of RLIP76 puriﬁed
from the wild-type NSCLC. After siRNA mediated depletion
of PKCa, DOX-transport activities of RLIP76 puriﬁed from
SCLC and NSCLC were indistinguishable. Depletion of PKCa
inhibited the growth of NSCLC more than SCLC cells
(70 ± 3% vs. 43 ± 5%, respectively). PKCa-depletion lowered
the IC50 of NSCLC cell lines for DOX to the same level as that
observed for SCLC. RLIP76/ mouse embryonic ﬁbroblasts
(MEFs) were signiﬁcantly more sensitive to DOX as compared
with RLIP76+/+ MEFs (IC50 25 vs. 125 nM, respectively). How-
ever, PKCa-depletion did not aﬀect DOX-cytotoxicity towards
RLIP76/ MEFs, as opposed to RLIP76+/+ MEFs which were
sensitized by 2.2-fold. These results demonstrate that RLIP76 is
a primary determinant of DOX-resistance, and that PKCa med-
iated accumulation defect and DOX-resistance in NSCLC is pri-
marily due to diﬀerential phosphorylation of RLIP76 in SCLC
and NSCLC.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Doxorubicin (DOX) is a highly eﬀective anthracycline che-
motherapeutic agent belonging to the natural products class
of antineoplastic agents. It is a highly active agent in the che-
motherapeutic treatment of a number of human malignancies
including breast cancer, bladder cancer, multiple myeloma,
lymphoma, and small cell lung cancer (SCLC) [1,2]. In contrast
to its high activity against small cell lung cancer, it is relatively
ineﬀective against non-small cell lung cancer (NSCLC), which
represents about 4/5 of all lung cancers. Even in SCLC, ac-
quired resistance to DOX is common, accounting for the fre-
quent failure to cure SCLC with DOX-based chemotherapy
regimens. The resistance mechanisms responsible for inherent
DOX-resistance of NSCLC and acquired DOX-resistance in
SCLC have been the subject of numerous investigations [3].
The inherently lower cellular accumulation of DOX in NSCLC
as compared with SCLC has been frequently attributed as a
major cause of DOX-resistance in NSCLC; increased pro-
tein-kinase-C (PKC) activity is closely linked with DOX-accu-
mulation defective resistance. The mechanism through which
PKC can inﬂuence cellular DOX-accumulation remains un-
clear since regulation of ABC-transporter activity by PKC
has not been established. PKCa has been shown to phosphor-
ylate and stimulate the activity of Ral-interacting protein
(RLIP76) [4–6], a novel non-ABC-transporter of DOX [7].
RLIP76 is a multifunctional modular protein, which was ini-
tially cloned as a Ral binding protein and was originally pre-
dicted to be a Ral-eﬀector [8] but the exact actions of this
eﬀector were not known. We cloned Ral-interacting protein
(RLIP76) independently in search of ATPases capable of and
being stimulated by glutathione electrophile conjugates (GS-
E), and have demonstrated that it is a stress-responsive protein
capable of providing protection to cells from a variety of oxi-
dative stressors including heat, UV-irradiation, X irradiation,
and oxidant chemicals and indeed does fulﬁll the original pre-
diction of RLIP76 being an eﬀector protein [9–11]; these stress-
ors are all known to cause formation of increased electrophilic
lipid peroxidation byproducts which are metabolized to GS-E.
GS-E are potent inhibitors of enzymes involved in glutathione-
linked oxidative stress defense, and our studies clearly show
that the transport activity of RLIP76 is important for the pro-
tective function of RLIP76. Recent studies by other investiga-
tors, showing that RLIP76 is a regulator of the Rho/Rac
subfamily of G-proteins, known regulators of xenobiotication of European Biochemical Societies.
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showing that RLIP76 is a multispeciﬁc transporter, suggest
that RLIP76 protects cells from apoptosis caused by drug/tox-
in/oxidant stresses by preventing cellular accumulation of
toxic-drugs and GS-E of endogenous and exogenous electro-
philic toxins through its transport activity [7,13].
Our recent studies in panels of SCLC and NSCLC have
shown that RLIP76 contributes approximately 2/3 of total
DOX-transport activity with the remainder being contributed
to by ABC transporters [14]. Similarly, RLIP76 was also found
to be the predominant GS-E transporter of the model substrate
LTC4 in cancer cells [15]. Greater than 80% loss in liver and
heart tissue of total DOX and GS-E transport activity in
RLIP76 knockout mice [16] strongly supports the hypothesis
that RLIP76 can contribute substantially to total DOX-trans-
port capacity in cancer cells. Sequence analysis of RLIP76 indi-
cates the presence of four potential PKCa phosphorylation sites
[6]. Since increased PKC activity is correlated with increased
DOX-resistance and decreased cellular DOX-accumulation,
and because RLIP76 can be activated through phosphorylation
by PKCa [4–6], the present studies were performed to test the
hypothesis that cellular RLIP76 levels and transport activity,
and the regulation of RLIP76 by PKCa is a signiﬁcant determi-
nant of inherent DOX-resistance in NSCLC.2. Materials and methods
2.1. Materials
Sources for reagents for tissue culture, protein puriﬁcation, and
transport studies were the same as previously reported [17]. [14C]-
DOX (speciﬁc activity 57 mCi/mmol) was purchased from Amersham
Corporation (Arlington Heights, IL). Source of anti-RLIP76 IgG used
in these studies were the same as previously described [9]. PKCa was
obtained from Molecular Probes, Oregon. Polyclonal rabbit-anti-
human PKCa IgG was purchased from Biosource (Camarillo, CA).
2.2. Method for preparing MEF cultures
Twelve weeks old C57BL/6 mice born of heterozygous · heterozy-
gous (RLIP76+/ · RLIP76+/) mating were genotyped by PCR strat-
egy on mouse tail DNA using forward, reverse and long terminal
region (LTR) primers. These mice were commissioned from Lexicon
Genetics andwere created usingCre-Lox technology. Embryo ﬁbroblast
lines were prepared from RLIP76+/+, RLIP76+/ and RLIP76/ mice
on the 13th or 14th day of pregnancy according to the method as
described previously [18].
2.3. Cell lines and cultures
Human SCLC lines, H182, H1417, H1618, NSCLC lines H226
(squamous cell carcinoma), H1395, H2347 (adenocarcinoma), and
H358 (bronchio alveolar) cell lines were used in present studies. All
cells were cultured at 37 C in a humidiﬁed atmosphere of 5% CO2
in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated
FBS, 1% (v/v) P/S solution, 2 mM L-glutamine, 10 mM HEPES,
1 mM sodium pyruvate, 4.5 g/L glucose, and 1.5 g/L sodium bicarbon-
ate.2.4. Drug sensitivity assay
Cell density was estimated by counting trypan blue excluding cells in
a hemocytometer, and 20000 cells/160 ll medium were plated into each
well of 96-well ﬂat-bottomed microtiter plates. After 24 h, an aliquot
of medium without drug (control) or containing diﬀerent concentra-
tions of drug was added to the wells and IC50 of drug was measured
96 h later by MTT assay as previously described [19]. Eight replicate
wells were used in each point in each of three separate measurement
of IC50. Measured absorbance values were directly linked with a
spreadsheet for calculation of IC50, deﬁned as the drug concentrationthat reduced formazan formation by 50%. For determination of the ef-
fect of PKCa siRNA #8, cells were incubated for 3 h with 2 lg/well
PKCa siRNA in Transmessenger Transfection Reagent (Qiagen). Cells
were then washed with PBS and MTT assay was performed 48 h after
treatment of siRNA as described above.
2.5. Puriﬁcation of RLIP76 from SCLC and NSCLC
Cells were pelleted at 700 · g. The pellets were suspended in PBS and
aliquots were taken for determining cell number and viability by
counting trypan blue dye excluding cells in a hemocytometer. Aﬃnity
puriﬁcation of RLIP76 from human lung cancer cell lines was per-
formed in a manner identical to that described previously [6]. Func-
tional reconstitution of puriﬁed RLIP76 into artiﬁcial liposomes and
transport activity in RLIP76 liposomes was measured as described pre-
viously [14,17].
2.6. Transport studies in RLIP76-liposomes
Transport studies of DOX in reconstituted vesicles were performed
by the method as described previously [9,14], using 250 ng protein
per 40 ll reaction mixture. Equimolar concentration of NaCl was
substituted for ATP in the controls. ATP-dependent uptake of 14-
[14C]-DOX (speciﬁc activity 8.5 · 104 cpm/nmol) was determined by
subtracting the radioactivity (cpm) of the control without ATP from
that of the experimental containing ATP, and the transport of DOX
was calculated in terms of nmol/min/mg protein. Liposomes prepared
without addition of RLIP76 were used for controls.
2.7. Stable transfection of RLIP76 and RLIP76delPKCa-sites in SCLC and
NSCLC cells
H1618 (SCLC) andH358 (NSCLC)were transfected with the eukary-
otic expression vector alone (pcDNA3.1) or with pcDNA3.1-RLIP76
and the mutants of RLIP76del PKCsite[aa 118–120 (SKK), 297–299 (TEK),
353–355 (SNR) and 509–511 (SEK)] using lipofectamine 2000 (Invitrogen).
RLIP76 lacking the PKCa -site, deletion mutants were made by
PCR-based site-directed mutagenesis as described previously [6]. Stable
transfectants were selected in the presence of 600 lg/ml G418 for 2
weeks. Several G418-resistant stable clones were selected for further
characterization and were maintained in medium containing 300 lg/
ml G418. Single clonal stable transfectants was established by
sequential dilution into 96-well plate, such that only a single cell was
seeded in each well. Expression of RLIP76 and its mutants mRNA in
lung cancer cell lines were evaluated by RT-PCR analysis.
2.8. RLIP76 siRNA preparation
We chose the region around the PKC site (nucleotide 1529–1549
starting from 1 AUG codon in the open reading frame) in the C-termi-
nal region of RLIP76 as the target region to design for siRNA to sup-
press the RLIP76 so that the mutant of RLIP76 lacking the PKC
binding site remains unaﬀected. We searched for 21 nucleotide se-
quence motif, AA(N19)TT and selected hits with approximately 50%
GC contents. The sequence of sense siRNA corresponds to N19. We
converted 3 0 end of the sense siRNA to TT. The rationale for this se-
quence conversion was to generate a symmetric duplex with respect to
the sequence composition of sense and antisense 3 0 overhangs. The
antisense siRNA was synthesized as the complement to position 1–
19 of the 21-nucleotide motif. The selected siRNA sequence was
blast-search (NCBI database) against EST libraries, to ensure that only
one gene is targeted. Chemically synthesized siRNA duplex in the 2 0
de-protected and desalted forms, was purchased from Dharmacon Re-
search (Lafayette, CO). A 21 nucleotide long scrambled siRNA duplex
was used as a control. The scrambled siRNA sequence was not homol-
ogous with RLIP76 mRNA in a blast-search against RLIP76. The siR-
NA duplex was re-suspended in 1· universal buﬀer, provided by
Dharmacon Research Laboratory. The targeted cDNA sequence
(AAAAAGAAGAGATTGAACGCC) corresponds to aa 509–511
(nucleotide 1529–1549). The corresponding sense and antisense siRNA
sequences are AAAGAAGAGAUUGAACGCCdTdT and GGCG-
UUCAAUCUCUUCUUUdTdT, respectively. The sequence of the
scrambled siRNA in the sense and antisense directions are GUA-
ACUGCAACGAUUUCGAUGdTdT and CAUCGAAAUCGUU-
GCAGUUACdTdT, respectively. Transfection of siRNA duplexes
were performed using Transmessenger Transfection Reagent kit (Qia-
gen) and assay for silencing 48 h after transfection.
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In this study, we prepared siRNA targeting human PKCa. We chose
aa 450–456 (nucleotide1348–1366, designated as # 8) and aa 654–660
(nucleotide 1960–1978, designated as # 9) starting from 1 AUG codon
in the open reading frame in the C-terminal region of PKCa as the tar-
get region to design for siRNA. The selected siRNA sequence was
blast-search (NCBI database) against EST libraries, to ensure that only
one gene is targeted. Chemically synthesized siRNA duplex in the 2 0
de-protected and desalted form was purchased from Dharmacon Re-
search. A 21 nucleotide long non-silencing siRNA duplex was used
as a control. The siRNA duplex was resuspended in 1· universal buf-
fer, provided by Dharmacon Research Laboratory. The targeted
cDNA sequence for # 8 (GGATTGTTCTTTCTTCATA) corresponds
to nt 1348–1366 and for # 9 (GAAGGGTTCTCGTATGTCA) corre-
sponds to nt 1960–1978. The corresponding sense and antisense siRNA
sequences for # 8 are GGAUUGUUCUUUCUUCAUAdTdT and
UAUGAAGAAAGAACAAUCCdTdT, for # 9 are GAAGGGUU-
CUCGUAUGUCAdTdT and UGACAUACGAGAACCCUUCdT-
dT, respectively. The sequence of the non-silencing control siRNA in
the sense and antisense directions are UUCUCCGAACGUGUCAC-
GUdTdT and ACGUGACACGUUCGGAGAAdTdT, respectively.
Transfection of siRNA duplexes was performed using Transmessenger
Transfection Reagent kit (Qiagen) and assay for silencing 48 h after
transfection.3. Results and discussion
3.1. Eﬀect of deletion of PKC-phosphorylation sites of RLIP76
in SCLC and NSCLC
In order to investigate diﬀerential phosphorylation of
RLIP76 by PKCa in the intact SCLC and NSCLC cells, we de-
vised a scheme for depleting wild-type RLIP76 in both cell
types after transfection with either empty vector, full length
RLIP76 or with RLIP76delPKCa-sites, a construct in which the
four potential PKCa phosphorylation sites have been deleted.
The siRNA siRLIP761529–1549 used to deplete wild-type
RLIP76 was reconstituted in the Transmessenger Transfection
Reagent Kit (Qiagen) and added to cells for 3 h, then washed
oﬀ. After 48 h incubation, remaining cells were harvested and0
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Fig. 1. Eﬀects on the speciﬁc activity for DOX-transport of expression of
NSCLC cell lines. RLIP76 was puriﬁed from H1618 SCLC and H358 NSC
RLIP76 (hatched bars) or RLIP76delPKCa-sites (gray bars), treated for 3 h wit
type RLIP76, and not RLIP76delPKCa-sites) or corresponding scrambled contr
Speciﬁc activity shown from (n = 12). DOX-transport activities obtained
reconstituted separately. Missing black or hatched bars are for the control ce
which undergo apoptosis upon depletion of wild-type RLIP76, and no RLIRLIP76 was puriﬁed, quantiﬁed by ELISA, and reconstituted
into artiﬁcial liposomes for measurement of ATP-dependent
DOX-transport activity. Proteoliposomes were pre-incubated
without or with PKCa and 1 mM ATP for 30 min prior to
transport measurement. RLIP76 puriﬁed from SCLC
(H1618) had half the speciﬁc activity of that puriﬁed from
NSCLC (H358). Pre-incubation with PKCa, stimulated the
activity of RLIP76 puriﬁed from either NSCLC or SCLC.
Depletion of RLIP76 using siRLIP761529–1549 resulted in
extensive apoptosis in cells transfected with either empty vec-
tor, or with full length RLIP76 and no RLIP76 could be puri-
ﬁed (Fig. 1). RLIP76 puriﬁed from cells transfected with
RLIP76delPKCa-sites without treatment with siRLIP761529–1549
(consisting of both the wild-type and mutant protein) had a
slightly lower speciﬁc activity and blunted stimulation of activ-
ity by PKCa. The speciﬁc activity of RLIP76 puriﬁed from
cells transfected with RLIP76delPKCa-sites and treated with siR-
LIP761529–1549 (to deplete wild-type RLIP76) was lower and
not signiﬁcantly aﬀected by PKCa. Remarkably, when wild-
type RLIP76 was depleted leaving only the mutant protein,
we did not observe apoptosis, indicating that the activity of
this mutant, though quite low, is adequate to prevent apopto-
sis under ambient culture conditions. Most importantly, puri-
ﬁed protein from both SCLC and NSCLC expressing
exclusively RLIP76delPKCa-sites (after treatment with siR-
LIP761529–1549) had roughly equal speciﬁc activity, certainly
much lower than that in wild-type NSCLC, and unaﬀected
by PKCa (Fig. 1). These ﬁndings strongly indicated that PKCa
mediated phosphorylation of RLIP76 in NSCLC, and lack
thereof in SCLC, is a major contributor to the diﬀerences in
speciﬁc activity of this protein between SCLC and NSCLC.
3.2. Eﬀect of PKCa-depletion on DOX-transport activity of
RLIP76 from SCLC and NSCLC
The above postulate predicts that depletion of PKCa should
have similar eﬀects on the speciﬁc activity of RLIP76 as did the -  +  -  +
 -  -  +  +
H358 NSCLC
tes
PKCa phosphorylation sites deletion mutant RLIP76 in SCLC and
LC cells transfected with either vector alone (black bar), full length
h either siRNA RLIP761529–1549 (which should selectively deplete wild-
ol siRNA, followed by harvesting cells at 48 h for protein puriﬁcation.
from studies in artiﬁcial liposomes into which each protein was
lls and those cells transfected with wild-type full length RLIP76, all of
P76 protein can be puriﬁed.
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test this postulate, we puriﬁed and measured DOX-transport
activity of RLIP76 from SCLC and NSCLC cell lines subject
to pre-treatment with siRNA for depletion of PKCa. Depletion
of PKCa by siRNA # 8 and # 9 (Fig. 2A and B, respectively)
was accomplished using a Qiagen Transmessenger Transfection
reagent kit. PKCa level was generally higher in NSCLC as com-
pared with SCLC, and complete depletion was demonstrated
for the three SCLC and four NSCLC cell lines within 48 h by
Western blot analyses (Fig. 2, panels A and B). Puriﬁed RLIP76
from cells treated either with PKCa siRNA # 8 or control
scrambled siRNA was reconstituted into artiﬁcial liposomes
and speciﬁc activity towards DOX-transport was measured.
After PKCa-depletion, the speciﬁc activity of RLIP76 from
all three SCLC and four NSCLC cell lines subjected to PKCa
depletion were indistinguishable (Fig. 3A), validating the asser-
tion that the higher speciﬁc activity of RLIP76 in NSCLC is lar-
gely due to greater activity of PKCa in NSCLC.
3.3. The eﬀect of PKCa depletion on DOX-cytotoxicity in
SCLC and NSCLC
To see how this diﬀerence in speciﬁc activity of RLIP76
translated into eﬀects on cell growth as well as DOX-cytotox-Fig. 2. Depletion of PKCa in SCLC and NSCLC by siRNA. H182, H1417 a
were treated with PKCa-siRNA # 8 (+) or corresponding scrambled siRNA
siRNA () (panel B) (Dharmacon) using Transmessenger Transfection Rea
allowed to grow in fresh complete medium for 48 h before preparation of ce
homogenate from all cell lines was applied to SDS–PAGE, immuno-blotted t
using rabbit-anti-human-PKCa antibodies (Biosource, CA) as primary antib
were developed using the chromogenic substrate, 4-chloro-1-naphthol. b-acticity, we compared cell growth and IC50 of DOX between cells
treated with PKCa siRNA # 8 or scrambled siRNA. PKCa-
depletion caused decrease in cell growth in SCLC by
43 ± 5% (n = 3), whereas in NSCLC, this eﬀect was
70 ± 3% (n = 4) (Fig. 3B).The eﬀect of PKCa-depletion on
DOX-cytotoxicity was much more marked in NSCLC as com-
pared with SCLC, as DOX-resistance of NSCLC was reduced
to the level found in SCLC (Fig. 3C). PKCa depletion in
SCLC sensitized DOX only slightly, presumably though other
pathways regulated by PKCa. Taken together, these studies
showed that PKCa is a primary determinant of the speciﬁc
activity of RLIP76, and that DOX-resistance correlates well
with the speciﬁc activity for DOX-transport by RLIP76.
3.4. Requirement of RLIP76 for PKCa mediated
DOX-resistance
If DOX-resistance conferred by PKCa was mediated pri-
marily through phosphorylation of RLIP76, PKCa-depletion
should not sensitize cells lacking RLIP76 to DOX. We thus
compared the eﬀects of PKCa depletion on cell growth and
DOX-cytotoxicity in RLIP76+/+ vs. RLIP76/ MEFs.
PKCa-depletion inhibited the growth of RLIP76+/+ MEFs
43 ± 11%, but RLIP76/ MEFs were unaﬀected (Fig. 4A).nd H1618 SCLC and H226, H358, H1395 and H2347 NSCLC cell lines
() (panel A) and PKCa-siRNA # 9 (+) or corresponding scrambled
gent (Qiagen) for 3 h followed by washing with PBS. Cells were then
ll homogenate for Western blotting. Protein (100 lg/lane) from crude
o nitrocellulose membranes, and Western blot analyses were performed
ody, and HRP conjugated goat-anti-rabbit secondary antibody. Blots
in was used as loading control.
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Fig. 3. Eﬀect of PKCa-depletion on cell survival, RLIP76 activity and DOX IC50 in SCLC and NSCLC H182, H1417 and H1618 SCLC and H226,
H358, H1395 and H2347 NSCLC cell lines were treated with PKCa-siRNA # 8 (open bars) or corresponding scrambled siRNA (ﬁlled bars)
(Dharmacon) using Transmessenger Transfection Reagent (Qiagen) for 3 h followed by washing with PBS. Cells were then allowed to grow in fresh
complete medium for 48 h prior to preparation of cell homogenate from which RLIP76 was puriﬁed to homogeneity using dinitrophenyl S-
glutathione aﬃnity chromatography as previously described [6]. Puriﬁed RLIP76 fractions were reconstituted into artiﬁcial cholesterol:asolectin
liposomes as previously described [9] and speciﬁc activity of DOX-transport was measured using 14C-DOX (sp. act. 8.5 · 104 cpm/nmol) (panel A).
For cell growth studies in the absence of DOX, cells were treated with PKCa siRNA # 8 or scrambled siRNA in the same manner as for panel A,
followed by inoculation of cells at 2 · 104 cell/well into 96 well plates. Viable cell density was determined at 96 h by addition of MTT (panel B). For
DOX-cytotoxicity studies, the same procedure was followed as in panel B, but DOX 0.01 to 2 lM was included in the 96 well plate (eight replicates
per concentration). The IC50 values were obtained from ﬁtting a modiﬁed Hill equation to data obtained from MTT assay (panel C). The values
presented in all panels are means and S.D. from three experiments each. Control siRNA treated (ﬁlled bars); PKCa siRNA treated (open bars).
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nitude more sensitive to DOX as compared with the wild-type
RLIP76+/+ MEFs (Fig. 4B and C). Though PKCa-depletion
clearly sensitized the RLIP76+/+ MEFs to DOX, this sensitiza-
tion was not to the level of that seen with RLIP76/ MEFs.
Most remarkably, PKCa-depletion had no eﬀect on the cyto-
toxicity of DOX in RLIP76/ MEFs, indicating that RLIP76is required to see the DOX-sensitizing eﬀect of PKCa-deple-
tion.
Results of present studies demonstrate that RLIP76 is a pri-
mary determinant of DOX-sensitivity, and that the DOX-resis-
tance mediating eﬀects of PKCa are mediated primarily
through phosphorylation and stimulation of RLIP76 transport
activity. These ﬁndings oﬀer a novel explanation for the previ-
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Fig. 4. Eﬀect of PKCa-depletion on cell survival and DOX IC50 in RLIP76
+/+ and RLIP76/ MEF cells. MEFs were cultured from the fetus at 12–
13 day gestation as previously described [18]. For cell growth studies in the absence of DOX, cells were treated with PKCa siRNA # 8 (open bars) or
scrambled siRNA (ﬁlled bars) in the same manner as for Fig. 3 panel A, followed by inoculation of cells at 2 · 104 cell/well into 96 well plates. Viable
cell density was determined at 96 h by addition of MTT (panel A). For DOX-cytotoxicity studies, the same procedure was followed as in Fig. 3 panel
C, DOX 0.01 to 2 lMwas included in the 96 well plate (eight replicates per concentration). The IC50 values were obtained from ﬁtting a modiﬁed Hill
equation to data obtained from MTT assay (panel B). The cytotoxicity curves for RLIP76+/+ and RLIP76/ MEFs treated either with scrambled or
PKCa-siRNA # 8 are presented (panel C). The values presented in all panels are means and S.D. from three experiments each. Control siRNA
treated (ﬁlled bars); PKCa siRNA treated (open bars).
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in PKC-overexpressing cells, and support previous studies in
which PKC activity has been proposed as a major determinant
of the inherent DOX-accumulation defect and resistance of
NSCLC [20]. Since RLIP76 is also involved in other signaling
pathways, our ﬁndings do not rule out the possibility that
PKCa-depletion interferes with other signaling functions of
RLIP76 in the Ral and Rho/Rac/cdc42 pathways [7]. The clo-
sely related roles of PKC and RLIP76 are supported by studies
showing that modulation of membrane structure and plastic-
ity, the Ras/Ral-GEF/Ral pathway, and Rho-family G-pro-
teins that regulate xenobiotic metabolism and stress–response
are directly aﬀected by both PKC and RLIP76 [7].
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